Expressable becomes the first speech-therapy provider on Amazon’s Health Benefits Connector, which matches shoppers to digital-health services their employer plans already cover.
Licensing HM17321 from Korea’s Hanmi, Roche is chasing the next frontier in weight loss: shedding fat while preserving the muscle that today’s GLP-1 drugs also strip away.
The Korean biotech will tap Eli Lilly’s labs, scientists and infrastructure to speed its RNA-based gene therapies — an incubator arrangement, not an acquisition.
Analyzing thousands of people, researchers found that drugs from antibiotics to antidepressants left fingerprints in the gut — some detectable years after the last dose.
The agency paused testing of RGX-121 after spinal MRI abnormalities turned up in patients treated years ago — the second clinical hold on a Regenxbio program in 2026.
The European Commission approved teclistamab plus daratumumab for relapsed multiple myeloma after a trial cut the risk of progression or death by more than 80%.
By testing half a million DNA variants, researchers pinned down the signature of the “initiator” — the element that marks where a gene is switched on — and found it in roughly 60% of human genes.
A new analysis of grocery data suggests banning soda from food-assistance benefits cut soda buying — but shoppers redirected much of the money to other sugary drinks.
In mice, the APOE4 variant raised a protein that made neurons smaller and overexcitable long before memory faltered — and dialing that protein back reversed the damage.
The renewed alliance keeps subspecialty expertise, tumor conferences and clinical-trial access available to patients closer to home, with new local cancer services coming this autumn.
The Phase 3 PreVenTB study of more than 12,000 people found the vaccines helped only certain groups against certain forms of tuberculosis — underscoring how hard a better TB shot remains.
NICE has backed Eli Lilly’s Onswik, a weekly insulin injection, for type 2 diabetes — cutting jabs by about 85% for patients who struggle with daily dosing, pending final approval.